
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is well-positioned for success with numerous development and commercialization partnerships, strong preliminary data for PD treatment and detection, and a well-developed pipeline targeting multiple neurodegenerative diseases. Despite a decrease in R&D expenses, the company is still able to maintain a healthy cash position. With a strong focus on precision medicine and a versatile platform, AC Immune has the potential to make significant strides in the treatment and detection of neurodegenerative diseases.
Bears say
AC Immune is heavily focused on targeting neurodegenerative diseases through its therapeutic and diagnostic products, but many of these are still in early stages of testing and have not yet proven their efficacy. This has resulted in a long timeline for potential readouts and delayed potential revenue. Additionally, there are concerns about the safety and effectiveness of their vaccines compared to traditional mAbs, which may limit their success in the increasingly competitive AD treatment market. Finally, their financials show consistently negative earnings and a high cash burn rate, indicating potential financial struggles down the line.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares